Mn Services Vermogensbeheer B.V. Sells 5,200 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Mn Services Vermogensbeheer B.V. reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 7.3% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 66,000 shares of the medical research company's stock after selling 5,200 shares during the period. Mn Services Vermogensbeheer B.V.'s holdings in IQVIA were worth $11,636,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. American National Bank & Trust bought a new position in shares of IQVIA in the first quarter worth about $26,000. ST Germain D J Co. Inc. raised its position in IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after purchasing an additional 76 shares during the last quarter. GKV Capital Management Co. Inc. bought a new position in IQVIA in the 4th quarter worth approximately $39,000. Lee Danner & Bass Inc. bought a new position in IQVIA in the 4th quarter worth approximately $44,000. Finally, Zions Bancorporation N.A. raised its position in shares of IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after acquiring an additional 85 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Up 0.3%

Shares of IQV traded up $0.53 during mid-day trading on Wednesday, hitting $154.63. 1,667,170 shares of the company's stock were exchanged, compared to its average volume of 1,628,015. The company has a market cap of $26.75 billion, a PE ratio of 21.07, a P/E/G ratio of 1.69 and a beta of 1.28. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $252.88. The company has a 50-day simple moving average of $147.84 and a 200 day simple moving average of $176.89. The company has a debt-to-equity ratio of 2.19, a current ratio of 0.82 and a quick ratio of 0.82.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. The business had revenue of $3.83 billion during the quarter, compared to the consensus estimate of $3.77 billion. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The firm's revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter last year, the firm earned $2.54 earnings per share. On average, research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on IQV shares. Truist Financial dropped their target price on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research report on Thursday, April 10th. Citigroup reiterated a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Barclays lowered their price target on IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a research note on Wednesday, May 7th. Hsbc Global Res cut IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Finally, Robert W. Baird lowered their target price on shares of IQVIA from $195.00 to $161.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Eight analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, IQVIA presently has an average rating of "Moderate Buy" and an average target price of $226.32.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.